Lepodisiran

Last updated
Lepodisiran
Clinical data
Other namesLY3819469; LY-3819469
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company. [1] [2]

As of March 31 of 2025, company trials in phase 2 of randomized, double-blind, placebo-controlled study resulted in significant reduction of genetically inherited cardiovascular risk factors such as heart attacks, strokes, thrombosis, nearly 94% from baseline. [3]

References

  1. ↑ Nissen, Steven E.; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F.; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J. (12 November 2023). "Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial". JAMA. 330 (21): 2075–2083. doi:10.1001/jama.2023.21835. ISSN   0098-7484. PMC   10641766 . PMID   37952254.
  2. ↑ Boyanovsky, Boris B. (July 2023). "Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management". Journal of Cardiovascular Pharmacology. 82 (1): 32–36. doi: 10.1097/FJC.0000000000001438 . PMID   37192439.
  3. ↑ "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels". Eli Lilly and Company web page. March 30, 2025. Retrieved March 31, 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.